Detalles de la búsqueda
1.
CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager.
Biochem Biophys Rep
; 29: 101205, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35071801
2.
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors.
Mol Cancer Ther
; 20(1): 109-120, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33203731
3.
COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
MAbs
; 12(1): 1792130, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32684124
4.
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
Mol Cancer Ther
; 17(1): 215-221, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29054986
5.
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.
J Immunol Res
; 2017: 5737159, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29075649
6.
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR.
Front Immunol
; 4: 505, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24409185
7.
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.
PLoS One
; 9(11): e104227, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25375638
8.
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.
J Cancer Res Clin Oncol
; 139(2): 315-25, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23073510
9.
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
Clin Cancer Res
; 16(2): 497-508, 2010 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20068083
Resultados
1 -
9
de 9
1
Próxima >
>>